阿茲海默症之血液生物標記

10.6666/ClinMed.202103_87(3).0023

陳廷斌

類澱粉蛋白（amyloid） ； 生物標記（biomarker） ； neurofilament ； tau

臨床醫學月刊

87卷3期（2021 / 03 / 26）

145 - 149

繁體中文

近年來檢驗技術改良造就血液生物標記研究的進步。血液乙型類澱粉蛋白、tau與neurofilament light是阿茲海默症中最具潛力的血液生物標記。當然，仍需更多研究確認它們是否可成為阿茲海默症篩檢、診斷、評估預後和監測病程進展的可靠工具，甚至，可能有助於研發控制阿茲海默症疾病進展的藥物。

1. Altuna-Azkargorta, M,Mendioroz-Iriarte, M(2020).Blood biomarkers in Alzheimer’s disease.Neurología (English Edition),5
2. Chen, T-B,Lee, Y-J,Lin, S-Y(2019).Plasma Aβ42Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment.Scientific Reports,9,13984.
3. de Wolf, F,Ghanbari, M,Licher, S(2020).Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.Brain,143,1220-1232.
4. DeMarshall, CA,Nagele, EP,Sarkar, A(2016).Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.Alzheimers Dement,3,51-62.
5. Dubois, B,Feldman, HH,Jacova, C(2014).Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.Lancet Neurol,13,614-629.
6. Gabelli, C(2020).Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease.Lab Precision Med,5,15.
7. Gupta, VB,Hone, E,Pedrini, S(2017).Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.Alzheimers Dement,8,60-72.
8. Gustaw-Rothenberg, KA,Siedlak, SL,Bonda, DJ(2010).Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.Experimental Gerontol,45,47-52.
9. Henriksen, K,O'Bryant, SE,Hampel, H(2014).The future of blood-based biomarkers for Alzheimer's disease.Alzheimers Dement,10,115-131.
10. Jack, CR., Jr.,Bennett, DA,Blennow, K(2018).NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement,14,535-562.
11. Jammeh, E,Zhao, P,Carroll, C(2016).Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease.Annu Int Conf IEEE Eng Med Biol Soc,2016,2415-2418.
12. Janelidze, S,Mattsson, N,Palmqvist, S(2020).Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.Nature Med,26,379-386.
13. Jellinger, KA,Janetzky, B,Attems, J(2008).Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?.J Cell Mol Med,12,1094-1117.
14. Khoury, R,Ghossoub, E(2019).Diagnostic biomarkers of Alzheimer’s disease: A state-of-the-art review.Biomark Neuropsychiatry,1,100005.
15. Li, D,Mielke, MM(2019).An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform.Neurol Ther,8,73-82.
16. Mattsson, N,Andreasson, U,Zetterberg, H(2017).Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.JAMA Neurol,74,557-566.
17. McKhann, GM,Knopman, DS,Chertkow, H(2011).The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement,7,263-269.
18. Mielke, MM,Hagen, CE,Xu, J(2018).Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.Alzheimers Dement,14,989-997.
19. Mietelska-Porowska, A,Wojda, U(2017).T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer’s Disease: Potential Pools of New Biomarkers.J Immunol Res,2017,1-17.
20. Nakamura, A,Kaneko, N,Villemagne, VL(2018).High performance plasma amyloid-β biomarkers for Alzheimer's disease.Nature,554,249-254.
21. O'Bryant, SE,Mielke, MM,Rissman, RA(2017).Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.Alzheimers Dement,13,45-58.
22. Park, JC,Han, SH,Yi, D(2019).Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.Brain,142,771-786.
23. Sun, Y,Lee, HJ,Yang, SC(2014).A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan.PloS One,9,e100303.
24. Weston, PSJ,Poole, T,Ryan, NS(2017).Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.Neurology,89,2167-2175.
25. Yang, SY,Chiu, MJ,Chen, TF(2017).Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Neurol Ther,6,37-56.
26. Zetterberg, H(2017).Applying fluid biomarkers to Alzheimer's disease.Am J Physiol Cell Physiol,313,C3-C10.
27. Zetterberg, H,Burnham, SC(2019).Blood-based molecular biomarkers for Alzheimer's disease.Molecular Brain,12,26.
28. Zetterberg, H,Skillbäck, T,Mattsson, N(2016).Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.JAMA Neurol,73,60-67.